No Longer Just Hematologic Malignancies

“In the early years, cord blood therapies treated primarily hematologic malignancies. Today it’s that, but also the treatment and cure of many other diseases,” said Filippo Milano, MD, PhD, vice chair of the scientific planning committee for the Cord Blood Connect international congress.

Dr. Milano, associate director of Cord Blood Transplantation at the Fred Hutchinson Cancer Research Center, says that the congress will offer an opportunity to interact with the pioneers in a very young field that is celebrating 30 years since the

first cord blood transplant. Also presenting at the anniversary congress will be today’s pioneers – the clinicians and investigators who are developing leading-edge therapies using components of cord blood and perinatal tissues.

“You’ll be able to hear and ask questions of experts in cord blood engineering, cord blood-derived immunotherapies, cord blood-derived MSCs, and cord blood regenerative medicine,” he said. “Really, a unique opportunity.”

In addition to numerous technical training and education sessions, the scientific sessions will include:

  • State of the science
  • Clinical outcomes overview
  • Advances in hematopoietic cell transplantation
  • Engineering of cord blood grafts
  • Cord blood-derived immunotherapies
  • The potential power of mesenchymal stem cells
  • Emerging uses of cord blood in regenerative medicine
  • Understanding and optimizing approaches to regulation of cellular therapies
  • The innovators – original pioneers and today’s pioneers

The international congress convenes Sept. 14-16 at the Loews Miami Beach Hotel. Preview the complete agenda for the congress.